参考文献：

1. J. Li, J. Zheng, S. Wang et al., Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. Front Physiol 8, 15 (2017).

2. R. R. Holman, M. A. Bethel, R. J. Mentz et al., Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377, 1228-1239 (2017).

3. https://professional.diabetes.org.

4. https://www.easd.org.

5. A. S. Alexopoulos, J. B. Buse, Initial injectable therapy in type 2 diabetes: key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism,  (2019).

6. A. C. Sposito, O Berwanger, LSF de Carvalho et al., GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 17(1), 157 (2018).

7. H. C. Gerstein, H. M. Colhoun, G. R. Dagenais et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121-130 (2019).

8. H. C. Gerstein, H. M. Colhoun, G. R. Dagenais et al., Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131-138 (2019).

9. Y. Wang, Q. Lu, SK Wu et al., Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation. Anal Chem. 2011 Apr 15;83(8):3133-40. 

10. C. Rosales, Fcgamma Receptor Heterogeneity in Leukocyte Functional Responses. Front Immunol 8, 280 (2017).

11. P. M. Hogarth, G. A. Pietersz, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 11, 311-331 (2012).

12. E. Zijlstra, L. Heinemann, L. Plum-Morschel, Oral insulin reloaded: a structured approach. J Diabetes Sci Technol 8, 458-465 (2014).

13. A. W. Michels, P. A. Gottlieb, Learning From Past Failures of Oral Insulin Trials. Diabetes 67,                                              1211-1215 (2018).